Rituximab in maintaining remission in adults with podocytopathy
Adult
Male
Nephrotic Syndrome
Glomerulosclerosis, Focal Segmental
Podocytes
Nephrosis, Lipoid
Calcineurin Inhibitors
Remission Induction
India
3. Good health
03 medical and health sciences
0302 clinical medicine
Recurrence
Outcome Assessment, Health Care
Humans
Female
Steroids
Prospective Studies
Age of Onset
Rituximab
Immunosuppressive Agents
DOI:
10.1111/nep.13717
Publication Date:
2020-04-16T08:55:10Z
AUTHORS (5)
ABSTRACT
Abstract Rituximab is currently used after the conventional agents have failed in management of steroid‐dependent (SD)/ steroid‐resistant (SR) podocytopathies and a safer toxicity profile. We report 53 adults with who were managed effectively CD19‐targeted rituximab therapy. Methods This was prospective study carried out at tertiary care centre India between January 2014 June 2019. Adults 16 60 years SD, frequently relapsing (FR), SR nephrotic syndrome (NS) due to podocytopathy received approach. Primary outcome: Percentage patients remission 6 12 months. Secondary last follow‐up, dose adverse events Results Fifty‐three SD/FR/SR NS rituximab. The median age time first injection 30.09 ± 13.21 (16.53) years. At infusion, all steroids and/or calcineurin inhibitors (CNIs). Fifty (94.33%) end months follow‐up (median: 36 months). mean total 1 year 788.7 128.1 (6 001 100) mg. (median months), 42 (79%) did not require any additional CNI or No serious noted. Conclusion therapy safe efficacious SD/SR adult podocytopathy. Also, effective maintaining treatment naïve SD FR
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (31)
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....